SPECIALTY / DIRECT CATALOG PRICING
PTD-DBM
PTD-DBM is a 25-residue protein-transduction-domain/Dishevelled-binding-motif peptide; PubChem records the sequence RRRRRRRRGGGGRKTGHQICKFRKC.
- Format
- Lyophilized research vial
- Listed formats
- 1
- Available now
- 0
- Catalog class
- Specialty
Choose a listed format
- 5 mgRequest current pricingRequest pricing
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
PTD-DBM is a 25-residue protein-transduction-domain/Dishevelled-binding-motif peptide; PubChem records the sequence RRRRRRRRGGGGRKTGHQICKFRKC.
The specialty classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Specialty
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- Contact for current availability
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
PTD-DBM is a 25-residue protein-transduction-domain/Dishevelled-binding-motif peptide; PubChem records the sequence RRRRRRRRGGGGRKTGHQICKFRKC.
- Research covered
- A published mechanistic study evaluated PTD-DBM in cellular and animal models of androgen-related hair loss, where it was used to interfere with CXXC5-Dishevelled binding and alter Wnt/beta-catenin pathway signaling.
- Important limit
- The evidence is preclinical and model-specific. It does not establish human outcomes, verify the catalog's 5 mg material, or demonstrate that every material sold as PTD-DBM has the PubChem-recorded sequence and modifications.
- Authoritative sources
FACTUAL FAQ
PTD-DBM catalog questions
What formats are currently listed?
5 mg. Current price and stock state appear above.
What did researchers study?
A published mechanistic study evaluated PTD-DBM in cellular and animal models of androgen-related hair loss, where it was used to interfere with CXXC5-Dishevelled binding and alter Wnt/beta-catenin pathway signaling.
What is the most important evidence limit?
The evidence is preclinical and model-specific. It does not establish human outcomes, verify the catalog's 5 mg material, or demonstrate that every material sold as PTD-DBM has the PubChem-recorded sequence and modifications.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →